Edition:
United Kingdom

Roche Holding AG (RO.S)

RO.S on Swiss Exchange

242.40CHF
2:08pm BST
Change (% chg)

CHF-0.60 (-0.25%)
Prev Close
CHF243.00
Open
CHF244.00
Day's High
CHF245.00
Day's Low
CHF242.40
Volume
17,271
Avg. Vol
29,182
52-wk High
CHF255.00
52-wk Low
CHF209.40

Chart for

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.97
Market Cap(Mil.): CHF214,033.70
Shares Outstanding(Mil.): 862.56
Dividend: 8.20
Yield (%): 3.31

Financials

  RO.S Industry Sector
P/E (TTM): 22.03 30.93 32.76
EPS (TTM): 11.25 -- --
ROI: 20.46 15.07 14.61
ROE: 46.88 16.59 16.33

BRIEF-Roche Canada Says Health Canada Approves Hemlibra For Hemophilia A Patients With Inhibitors

* HEALTH CANADA APPROVES HEMLIBRA® FOR HEMOPHILIA A PATIENTS WITH INHIBITORS Source text for Eikon: Further company coverage:

14 Aug 2018

Bank DNB switches US, Europe mutual funds to index tracking

OSLO, Aug 14 Norwegian bank DNB will switch its mutual funds for U.S. and European stocks to index tracking from active management on Aug. 16, it said on Tuesday.

14 Aug 2018

Swiss stocks - Factors to watch on July 27

ZURICH, July 27The Swiss blue-chip SMI was seen opening 0.1 percent down at 9,135 points on Friday, according to premarket indications by bank Julius Baer .

27 Jul 2018

UPDATE 1-Switzerland's Vontobel lifts 2020 goals after buying private bank Notenstein

* CEO sees profitability hike, despite difficult markets (Adds comment from CEO, details throughout)

27 Jul 2018

Roche lifts veil on patent that earned it billions but soon expires

ZURICH Roche on Thursday lifted its veil of secrecy over a patent that has reaped billions of dollars over the years but is due to expire on Dec. 18, depriving the Swiss drugmaker of a key source of income.

26 Jul 2018

Roche lifts veil on patent that earned it billions but soon expires

ZURICH, July 26 Roche on Thursday lifted its veil of secrecy over a patent that has reaped billions of dollars over the years but is due to expire on Dec. 18, depriving the Swiss drugmaker of a key source of income.

26 Jul 2018

Upbeat Roche bests rival Novartis as new drugs fuel growth

ZURICH Swiss drugmaker Roche on Thursday outshone crosstown rival Novartis by boosting its 2018 sales outlook, helped by new medicines in a year when many feared patent expirations and cheaper copies would put growth at risk.

26 Jul 2018

Upbeat Roche bests rival Novartis as new drugs fuel growth

ZURICH Swiss drugmaker Roche on Thursday outshone crosstown rival Novartis by boosting its 2018 sales outlook, helped by new medicines in a year when many feared patent expirations and cheaper copies would put growth at risk.

26 Jul 2018

UPDATE 2-Upbeat Roche bests rival Novartis as new drugs fuel growth

* Shares rise 3 percent (Adds comment from CEO, analyst, details about rivals)

26 Jul 2018

Roche raises outlook for 2018 as new drugs gain traction

ZURICH, July 26 Swiss drugmaker Roche lifted its 2018 outlook on Thursday for the second time this year, after first-half sales and profit easily beat analyst expectations on the strength of newer drugs including multiple sclerosis treatment Ocrevus.

26 Jul 2018

Earnings vs. Estimates